New-onset diabetes after kidney transplantation: Prevalence, risk factors, and management

Transplantation

Volumn 93, Issue 12, 2012, Pages 1189-1195

  Sarno, Gerardo ^a,b   Muscogiuri, Giovanna ^a   De Rosa, Paride ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

Author keywords

Antihyperglycemic agents; Diabetes mellitus; Immunosuppressive therapy; Insulin; Kidney transplantation; Posttransplant complications

Indexed keywords

ANTIDIABETIC AGENT; BASILIXIMAB; BELATACEPT; CYCLOSPORIN A; HEMOGLOBIN A1C;

CLINICAL PROTOCOL; DIABETES MELLITUS; DIABETOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NEW ONSET DIABETES AFTER KIDNEY TRANSPLANTATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; WEIGHT CONTROL; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTORS;

MLCS; MLOWN;

EID: 84875308839     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824db97d     Document Type: Review

References (73)

1. Hjelmesaeth J, Hartmann A, Leivestad T., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
2. Bee YM, Tan HC, Tay T.L., et al. Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Ann Acad Med Singapore 2011; 40: 160.
3. Cosio FG, Pesavento TE, Kim S, et al Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440.
4. Luan FL, Steffick DE, Ojo AO New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011; 91: 334.
5. Pham PT, Pham PM, Pham S.V., et al. New onset diabetes after transplantation (NODAT): An overview. Diabetes Metab Syndr Obes 2011; 4: 175.
6. Kuo HT, Sampaio MS, Vincenti F, et al Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: An analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56: 1127.
7. Kasiske BL, Snyder JJ, Gilbertson D, et al Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
8. Joss N, Staatz CE, Thomson A.H., et al. Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007; 21: 136.
9. Woodward RS, Schnitzler MA, Baty J, et al Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
10. Nam JH, Mun JI, Kim S.I., et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417.
11. Iida S, Ishida H, Tokumoto T., et al. New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: Longterm impact and utility of the pre-transplant OGTT. Int Urol Nephrol 2010; 42: 935.
12. Jardine AG, Gaston RS, Fellstrom B.C., et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378: 1419.
13. Alvarez A, Fernandez J, Porrini E., et al. Carotid atheromatosis in nondiabetic renal transplant recipients: The role of prediabetic glucose homeostasis alterations. Transplantation 2007; 84: 870.
14. Caillard S, Eprinchard L, Perrin P., et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: Role of systematic screening by oral glucose tolerance test. Transplantation 2011; 91: 757.
15. Mathew JT, Rao M, Job V., et al. Post-transplant hyperglycaemia: A study of risk factors. Nephrol Dial Transplant 2003; 18: 164.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(suppl 1): S5.
17. Chakkera HA, Weil EJ, Castro J, et al Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol 2009; 4: 853.
18. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
19. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(suppl 3): S1.
20. Davies MJ, Raymond NT, Day J.L., et al. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000; 17: 433.
21. Valderhaug TG, Jenssen T, Hartmann A., et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88: 429.
22. Bergrem HA, Valderhaug TG, Hartmann A, et al Undiagnosed diabetes in kidney transplant candidates: A case-finding strategy. Clin J Am Soc Nephrol 2010; 5: 616.
23. Cosio FG, Pesavento TE, Osei K, et al Post-transplant diabetes mel-litus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732.
24. Sumrani NB, Delaney V, Ding Z.K., et al. Diabetes mellitus after renal transplantation in the cyclosporine eraVAn analysis of risk factors. Transplantation 1991; 51: 343.
25. Chow KM, Szeto CC, Li PK Good metabolic control using tacrolimus-based immunosuppressants in primary cadaveric renal transplantation in ChineseYa preliminary report. Clin Transplant 2002; 16: 39.
26. Cheung CY, Wong KM, Chan H.W., et al. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Transpl Int 2006; 19: 657.
27. Rodrigo E, Fernandez-Fresnedo G, Valero R., et al. New-onset diabetes after kidney transplantation: Risk factors. J Am Soc Nephrol 2006; 17(12 Suppl 3): S291.
28. Bayes B, Granada ML, Pastor M.C., et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416.
29. Ibernon M, Moreso F, Moreno J.M., et al. Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation. Transplantation 2009; 88: 272.
30. Hjelmesaeth J, Hartmann A, Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979.
31. Numakura K, Satoh S, Tsuchiya N., et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005; 80: 1419.
32. Bamoulid J, Courivaud C, Deschamps M., et al. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006; 17: 2333.
33. Ghisdal L, Baron C, Le Meur Y, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009; 20: 2459.
34. Yang J, Hutchinson II, Shah T, et al Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 2011; 91: 1114.
35. Ergün I., Keven K, Sengül S, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism predicts new onset diabetes mellitus after transplantation in kidney allograft recipients treated with cyclo-sporin A. Int Urol Nephrol 2011; 43: 543.
36. Kamar N, Toupance O, Buchler M., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092.
37. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416.
38. Pazienza V, Clement S, Pugnale P., et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164.
39. Del Campo J.A., Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: A way out for the virus? World J Gastroenterol 2009; 15: 5014.
40. Pittas AG, Joseph NA, Greenberg AS Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447.
41. Kanety H, Feinstein R, Papa M.Z., et al. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 1995; 270: 23780.
42. Bloom RD, Lake JR Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6: 2232.
43. Montori VM, Basu A, Erwin P.J., et al. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002; 25: 583.
44. Kamar N, Mariat C, Delahousse M., et al. Diabetes mellitus after kidney transplantation: A French multicentre observational study. Nephrol Dial Transplant 2007; 22: 1986.
45. Vincenti F, Friman S, Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
46. Davidson J, Wilkinson A, Dantal J., et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75(10 Suppl): SS3.
47. Augustine JJ, Hricik DE Steroid sparing in kidney transplantation: Changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006; 1: 1080.
48. Pascual J, Zamora J, Galeano C., et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009: CD005632.
49. Woodle ES, First MR, Pirsch J, et al A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose cortico-steroid therapy. Ann Surg 2008; 248: 564.
50. Paty BW, Harmon JS, Marsh C.L., et al. Inhibitory effects of immu-nosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002; 73: 353.
51. Duijnhoven EM, Boots JM, Christiaans M.H., et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 583.
52. Tavira B, Coto E, Diaz-Corte C, et al. KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients. Clin Transplant 2011; 25: E284.
53. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128.
54. Johnston O, Rose CL, Webster A.C., et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
55. Aasebo W, Midtvedt K, Valderhaug T.G., et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010; 25: 1289.
56. Vanrenterghem Y, Bresnahan B, Campistol J., et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91: 976.
57. Roland M, Gatault P, Al-Najjar A, et al. Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2008; 8: 1719.
58. Myslak M, Am H, Morales P., et al. Interpreting post-transplant pro-teinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6: 1660.
59. Osorio JM, Bravo J, Perez A., et al. Magnesemia in renal transplant recipients: Relation with immunosuppression and posttransplant diabetes. Transplant Proc 2010; 42: 2910.
60. Van Laecke S., Van Biesen W, Verbeke F, et al Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9: 2140.
61. Chaudhary DP, Sharma R, Bansal DD Implications of magnesium deficiency in type 2 diabetes: A review. Biol Trace Elem Res 2010; 134: 119.
62. Nijenhuis T, Hoenderop JG, Bindels RJ Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004; 15: 549.
63. Stevens RB, Lane JT, Boerner B.P., et al. Single-dose rATG induction at renal transplantation: Superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant 2012; 26: 123.
64. de Mattos A.M., Olyaei AJ, Prather J.C., et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005; 67: 714.
65. Hamer RA, Chow CL, Ong A.C., et al. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83: 36.
66. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353.
67. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854.
68. Lalau JD, Lacroix C, Compagnon P., et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779.
69. Marchetti P. New-onset diabetes after liver transplantation: From pathogenesis to management. Liver Transpl 2005; 11: 612.
70. Pollock SH, Reichbaum MI, Collier B.H., et al. Inhibitory effect of cyclosporine A on the activity of oral hypoglycemic agents in rats. J Pharmacol Exp Ther 1991; 258: 8.
71. Srinivasan BT, Jarvis J, Khunti K., et al. Recent advances in the management of type 2 diabetes mellitus: A review. Postgrad Med J 2008; 84: 524.
72. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361.
73. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE system of intensive diabetes self-managementV2000 update. Endocr Pract 2000; 6: 43.